Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Re-VOLVE: Biomarker-Guided Treatment in Ovarian Cancer
NCT05065021Phase 2Recruiting
- Sponsor
- University Health Network
- Start
- Feb 2023
- Primary completion
- Jun 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of dostarlimab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by University Health Network. Started Feb 2023; status: recruiting.
02
Drugs
dostarlimab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT05065021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05065021.